Table 2

Procedural characteristics

Early generation TAVI devicesNewer generation TAVI devicesP value
n=391n=391
Procedure time (min)68.76±34.1663.24±27.810.014
Amount of contrast (mL)234±99161±57<0.001
General anaesthesia, n (%)66 (16.9%)59 (15.1%)0.558
Sheath size (mean±SD)18.04±1.6215.71±2.53<0.001
Predilatation, n (%)346 (88.5%)230 (58.8%)<0.001
Postdilatation, n (%)93 (23.6%)76 (19.2%)0.162
Concomitant percutaneous coronary intervention23 (7.7%)41 (11.5%)0.113
Device features
  Medtronic CoreValve, n (%)201 (51.4%)
  Edwards SAPIEN THV/XT, n (%)190 (48.6%)
  Edwards SAPIEN 3, n (%)190 (48.6%)
  BSC LOTUS, n (%)96 (24.6%)
  Medtronic Evolut R, n (%)105 (26.9%)
Postprocedure aortic regurgitation, n (%)n=387n=389<0.001
  None or mild340 (87.9%)377 (96.9%)<0.001
  Moderate or severe47 (12.1%)12 (3.1%)<0.001
Procedural complications
  Valve in series7 (1.8%)4 (1.0%)0.546
  Repeat unplanned intervention2 (0.5%)6 (1.5%)0.287
  Annulus rupture/aortic dissection, n (%)0 (0.0%)8 (2.0%)0.008
  Valve dislocation/embolisation, n (%)11 (4.0%)3 (0.8%)0.005
  Conversion to SAVR, n (%)4 (1.0%)2 (0.5%)0.686
  Coronary artery occlusion, n (%)3 (1.1%)3 (0.8%)0.696
  • BSC, Boston Scientific; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve.